Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019066603) PERSISTENT PROTEIN CONJUGATE WITH IMPROVED EFFICIENCY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/066603 International Application No.: PCT/KR2018/011616
Publication Date: 04.04.2019 International Filing Date: 01.10.2018
IPC:
C07K 19/00 (2006.01) ,C07K 14/62 (2006.01) ,A61K 47/54 (2017.01) ,A61K 47/68 (2017.01) ,A61K 38/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
19
Hybrid peptides
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
575
Hormones
62
Insulins
[IPC code unknown for A61K 47/54][IPC code unknown for A61K 47/68]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
Applicants:
한미약품 주식회사 HANMI PHARM. CO., LTD. [KR/KR]; 경기도 화성시 팔탄면 무하로 214 214, Muha-ro, Paltan-myeon, Hwaseong-si, Gyeonggi-do 18536, KR
Inventors:
이종수 LEE, Jong-Soo; KR
김은정 KIM, Eun Jung; KR
김대진 KIM, Dae Jin; KR
Agent:
손민 SON, Min; KR
Priority Data:
10-2017-012741829.09.2017KR
Title (EN) PERSISTENT PROTEIN CONJUGATE WITH IMPROVED EFFICIENCY
(FR) CONJUGUÉ DE PROTÉINE PERSISTANT À EFFICACITÉ AMÉLIORÉE
(KO) 효력이 향상된 지속성 단백질 결합체
Abstract:
(EN) The present invention relates to a protein conjugate, in which a physiologically active polypeptide modified with a fatty acid molecule and an immunoglobulin Fc region are linked through a non-peptide polymer linker, a pharmaceutical composition comprising the same, and a method for preparing the protein conjugate. The protein conjugate extends the blood half-life of the physiologically active polypeptide through the linkage of the binding site of immunoglobulin Fc and the intramolecular bonding of the fatty acid molecule; has an excellent in vivo activity; and provides a protein conjugate having no risk of inducing an immune response.
(FR) L'invention concerne un conjugué de protéine, dans lequel un polypeptide physiologiquement actif modifié avec une molécule d'acide gras et une région Fc de l'immunoglobuline sont liés par l'intermédiaire d'un lieur polymère non peptidique. L'invention concerne également une composition pharmaceutique le comprenant, ainsi qu'un procédé de préparation de ce conjugué de protéine. Le conjugué de protéine selon l'invention prolonge la demi-vie dans le sang du polypeptide physiologiquement actif par la liaison du site de liaison de la région Fc de l'immunoglobuline et du lien intramoléculaire de la molécule d'acide gras ; présente une excellente activité in vivo ; et ne présente pas de risque d'induire une réponse immunitaire.
(KO) 본 발명은 지방산 분자로 개질된 생리활성 폴리펩타이드 및 면역글로불린 Fc 영역이 비펩타이드성 중합체 링커를 통하여 연결된, 단백질 결합체 및 이를 포함하는 약학적 조성물, 및 상기 단백질 결합체를 제조하는 방법에 관한 것이다. 상기 단백질 결합체는 면역글로불린 Fc의 결합부위의 연결과 지방산 분자의 물질 내 결합을 통하여, 생리활성 폴리펩타이드의 혈중 반감기를 연장시키고, 우수한 생체 내 역가를 가지며, 면역 반응 유발의 위험이 없는 단백질 결합체를 제공한다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)